Lidokain Kabi (Lidocaine Hydrochloride Monohydrate)

Lidokain Kabi is a local anesthetic used in various clinical settings to block nerve transmission.

• Local anesthesia: provides numbing of tissue for minor surgical or diagnostic procedures.
• Regional anesthesia: enables nerve block for limb or trunk surgeries, facilitating operative comfort.
• Pain management: offers short‑term relief of acute procedural pain and can be used as an adjunct in postoperative analgesia.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions required for depolarization. This inhibition stops the initiation and propagation of nerve impulses, resulting in reversible loss of sensation in the administered area.

Lidokain Kabi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Tingling or numbness at the injection site
• Transient hypotension or bradycardia
• Metallic taste in the mouth
• Light‑headedness or dizziness
• Nausea or mild vomiting

Serious or Rare Side Effects

• Cardiac arrhythmias, including ventricular tachycardia
• Seizures, especially with high plasma concentrations
• Methemoglobinemia, presenting as cyanosis
• Severe allergic reactions such as anaphylaxis
• Respiratory depression in susceptible individuals

Prior to using Lidokain Kabi, clinicians should consider several safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular monitoring: observe for bradycardia or hypotension during administration.
• Dose limitation: adhere to recommended maximum dose to avoid systemic toxicity.
• Concurrent CNS depressants: use caution when combined with other agents that lower seizure threshold.
• Pregnancy and lactation: evaluate risk‑benefit, limited data are available.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Lidokain Kabi can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase plasma lidocaine levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise lidocaine concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance hypotensive effect.
• General anesthetics (e.g., propofol): additive CNS depression.
• Diuretics (e.g., furosemide): may affect plasma protein binding and alter free drug levels.